AbCellera Biologics Inc (ABCL) concluded trading on Thursday at a closing price of $2.36, with 2.77 million shares of worth about $6.54 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.35% during that period and on March 27, 2025 the price saw a loss of about -2.48%. Currently the company’s common shares owned by public are about 295.76M shares, out of which, 223.58M shares are available for trading.
Stock saw a price change of -0.84% in past 5 days and over the past one month there was a price change of -19.18%. Year-to-date (YTD), ABCL shares are showing a performance of -19.45% which decreased to -48.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.11 but also hit the highest price of $4.75 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 4.10 million. The stock is currently trading -1.84% below its 20-day simple moving average (SMA20), while that difference is down -17.52% for SMA50 and it goes to -16.62% lower than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 295.76M outstanding shares and institutions hold larger chunk of about 37.05% of that.
The stock has a current market capitalization of $703.25M and its 3Y-monthly beta is at 0.45. It has posted earnings per share of -$0.55 in the same period. It has Quick Ratio of 9.81 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 5.96% while standing at 6.87% over the month.
Stock’s fiscal year EPS is expected to drop by -10.53% while it is estimated to decrease by -6.97% in next year. EPS is likely to grow at an annualized rate of -9.14% for next 5-years, compared to annual growth of -107.74% made by the stock over the past 5-years.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
